We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 07, 2021

Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients Treated With PARP Inhibitors

The Lancet Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Myelodysplastic Syndrome and Acute Myeloid Leukaemia in Patients Treated With PARP Inhibitors: A Safety Meta-Analysis of Randomised Controlled Trials and a Retrospective Study of the WHO Pharmacovigilance Database
Lancet Haematol 2020 Dec 18;[EPub Ahead of Print], PM Morice, A Leary, C Dolladille, B Chrétien, L Poulain, A González-Martín, K Moore, EM O'Reilly, I Ray-Coquard, J Alexandre

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading